UnknownNot Applicable

Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function

Finland100 participantsStarted 2015-06

Plain-language summary

The purpose of this study is to investigate local activation of the coagulation system in the kidney graft during organ preservation and during early reperfusion in adult kidney transplantation. Generation of thrombin and fibrin as well as activation and inhibition of fibrinolysis will be investigated. Influence of these events on delayed graft function (DGF) and acute cell-mediated rejection will be evaluated.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adult person (over 18 years old) * cadaveric transplantation * conventional standard immunosuppression plan (methylprednisolone, cyclosporin A, mycophenolate mofetil) Exclusion Criteria: * previous kidney transplant * other than local standard immunosuppression * panel reactive antibodies (PRA) \>30% * warfarin therapy * dual anti-platelet therapy * use of low molecular weight heparins (LMWH) or fondaparinux during last two weeks before surgery for other indication than hemodialysis

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Trans-renal difference/ratio of plasma concentrations of coagulation measurements

Timeframe: Two minutes after reperfusion of the kidney transplant

Delayed Graft Function

Timeframe: During 1 week after kidney transplantation

Acute cell mediated graft rejection

Timeframe: During 3 months after kidney transplantation

Trial details

NCT IDNCT02568696

SponsorHelsinki University Central Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-12-31

View on ClinicalTrials.gov More End Stage Renal Disease trials